Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $57.98 in the prior trading day, Soleno Therapeutics Inc (NASDAQ: SLNO) closed at $59.21, up 2.12%. In other words, the price has increased by $2.12 from its previous closing price. On the day, 1.62 million shares were traded. SLNO stock price reached its highest trading level at $60.29 during the session, while it also had its lowest trading level at $56.5.
Ratios:
Our goal is to gain a better understanding of SLNO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.01 and its Current Ratio is at 15.13. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on August 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $123.
On June 23, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $110.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 3146715904 and an Enterprise Value of 2912644096. For the stock, the TTM Price-to-Sale (P/S) ratio is 96.35 while its Price-to-Book (P/B) ratio in mrq is 12.44. Its current Enterprise Value per Revenue stands at 89.189 whereas that against EBITDA is -15.803.
Stock Price History:
The Beta on a monthly basis for SLNO is -2.90, which has changed by 0.24312413 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -14.70%, while the 200-Day Moving Average is calculated to be -8.82%.
Shares Statistics:
The stock has traded on average 1.85M shares per day over the past 3-months and 2162260 shares per day over the last 10 days, according to various share statistics. A total of 50.44M shares are outstanding, with a floating share count of 46.02M. Insiders hold about 13.40% of the company’s shares, while institutions hold 96.94% stake in the company. Shares short for SLNO as of 1757894400 were 7246780 with a Short Ratio of 3.92, compared to 1755216000 on 6307850. Therefore, it implies a Short% of Shares Outstanding of 7246780 and a Short% of Float of 15.57.
Earnings Estimates
Soleno Therapeutics Inc (SLNO) is presently subject to a detailed evaluation by 11.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is $0.21, with high estimates of $0.62 and low estimates of -$0.41.
Analysts are recommending an EPS of between $0.24 and -$1.69 for the fiscal current year, implying an average EPS of -$0.69. EPS for the following year is $3.02, with 11.0 analysts recommending between $5.56 and $1.01.
Revenue Estimates
For the next quarter, 10 analysts are estimating revenue of $61.92M. There is a high estimate of $83M for the next quarter, whereas the lowest estimate is $40.2M.
Based on 10 analysts’ estimates, the company’s revenue will be $398.08M in the next fiscal year. The high estimate is $551.75M and the low estimate is $252.18M.
